Breaking News

Lightlake Inks Manufacturing Contract for Naloxone

July 9, 2014

Will enable commercialization on a global scale

Lightlake Therapeutics, Inc. has signed an agreement with a commercial contract manufacturer for the production of its naloxone-based opioid overdose reversal treatment. The manufacturer will provide the manufacturing capacity needed at cGMP production facilities to enable commercialization of the treatment on a global scale.

Naloxone is an injectable drug that can reverse the overdose of prescription and illicit opioids. Lightlake has been developing an intranasal delivery system that could expand its availability and use in preventing opioid overdose deaths.

"This is a significant milestone for Lightlake in forwarding our opioid overdose reversal treatment," said Dr. Roger Crystal, chief executive officer of Lightlake. "We have been diligent in selecting our partner for the contract manufacturing process to best position us to produce a high quality treatment that can meet the requirements for FDA approval. We are confident that working with this partner will help us better serve the market need for a needleless treatment and provide us with significant competitive advantages."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks